Monkeypox Stocks: SIGA, EBS and TNXP Move Higher on Smallpox Vaccines, TreatmentsInvestorPlace • 05/20/22
SIGA Receives Approval from the FDA for Intravenous (IV) Formulation of TPOXX® (tecovirimat)GlobeNewsWire • 05/19/22
New Contract Awarded by U.S. Department of Defense for the Procurement of up to Approximately $7.5 Million of Oral TPOXX®GlobeNewsWire • 05/12/22
SIGA Technologies, Inc. (SIGA) CEO Phillip Gomez on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/08/22
SIGA Technologies to Host Business Update Call on May 5th, 2022 Following Release of First Quarter 2022 Financial ResultsGlobeNewsWire • 04/28/22
SIGA Technologies, Inc. (SIGA) CEO Phillip Gomez on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/04/22
SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2021GlobeNewsWire • 03/03/22
SIGA Announces Start of TPOXX® Post-Exposure Prophylactic (“PEP”) Clinical TrialsGlobeNewsWire • 03/02/22
SIGA Technologies to Host Business Update Call on March 3rd, 2022 Following Release of Fourth Quarter and Full Year 2021 Financial ResultsGlobeNewsWire • 02/24/22
SIGA Technologies to Participate in Edison Group's Global Healthcare “Open House” Virtual Conference from January 25-27th, 2022GlobeNewsWire • 01/18/22